• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Glaukos Corp (NY: GKOS )

    143.04 +1.29 (+0.91%)
    Official Closing Price Updated: 7:00 PM EST, Nov 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Glaukos Corp

    < Previous 1 2 3 4 5 Next >
    Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds
    Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds. 
    Via Benzinga
    How Is The Market Feeling About Glaukos?
    Via Benzinga
    A Closer Look at 7 Analyst Recommendations For Glaukos
    Via Benzinga
    Navigating 11 Analyst Ratings For Glaukos
    Via Benzinga
    Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
    Via Benzinga
    Meta To Rally Around 35%? Here Are 10 Top Analyst Forecasts For Thursday
    Via Benzinga
    10 Analysts Have This To Say About Glaukos
    Via Benzinga
    Deep Dive Into Glaukos Stock: Analyst Perspectives (12 Ratings)
    Via Benzinga
    Analyst Ratings For Glaukos
    Via Benzinga
    5 Analysts Have This To Say About Glaukos
    Via Benzinga
    GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q2 2024
    GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    7 Leading MedTech Stocks for Next-Gen Health Solutions
    With healthcare innovations promising to deliver groundbreaking solutions, these MedTech stocks should be on your radar. 
    Via InvestorPlace
    This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
    Via Benzinga
    Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' Analyst
    Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving stock up 6.22%. 
    Via Benzinga
    Topics Earnings
    Exposures Financial
    C.H. Robinson Worldwide Posts Upbeat Results, Joins Avis Budget Group, Qualcomm, BorgWarner, Moderna And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Glaukos: Q4 Earnings Insights
    Via Benzinga
    Earnings Scheduled For February 21, 2024
    Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million. 
    Via Benzinga
    GKOS Stock Earnings: Glaukos Misses EPS, Beats Revenue for Q1 2024
    GKOS stock results show that Glaukos missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
    U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    Analyst Ratings For Glaukos
    Via Benzinga
    Glaukos' Newly Approved Glaucoma Treatment Is The 'Biggest Driver To Watch': Analyst
    Shares of Glaukos Corp (NYSE: GKOS) continued to climb in early trading on Thursday, after the company’s iDose TR (travoprost intracameral implant) received U.S. 
    Via Benzinga
    Unveiling 7 Analyst Insights On Glaukos
    Via Benzinga
    Analyst Ratings for Glaukos
    Via Benzinga
    4 Analysts Have This to Say About Glaukos
    Via Benzinga
    Amazon.com To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Thursday
    Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
    Via Benzinga
    iDoseTR Approval Sets Stage for Glaukos' Game-Changing Product, Surpassing Market Expectations, Says Analyst
    Thursday, the FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog... 
    Via Benzinga
    Exposures Product Safety
    Dow Extends Rally As Treasury Yields Tank
    The Dow Jones Industrial Average is charging full speed ahead, up 78 points this afternoon after yesterday closing at record highs, on the heels of the Federal Reserve's rate decision. 
    Via Talk Markets
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    FDA Approves Glaukos' Eye Implant To Treat Eye Pressure In Glaucoma Patients
    The FDA approved Glaukos Corporation's (NYSE: GKOS) marketing application for a single administration per eye of iDose TR (travoprost intracameral implant) 75 mcg, a prostaglandin analog indicated for... 
    Via Benzinga
    Exposures Product Safety
    8 Analysts Have This to Say About Glaukos
    Via Benzinga
    < Previous 1 2 3 4 5 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.